Literature DB >> 34688011

Built-in adjuvants for use in vaccines.

Qianqian Li1, Zhimei Li2, Nan Deng3, Feiqing Ding3, Yiliang Li4, Hui Cai5.   

Abstract

Vaccine refers to biological products that are produced using various pathogenic microorganisms for inoculation. The goal of vaccination is to induce a robust immune response against a specific antigen, thus preventing the organism from getting infected. In vaccines, adjuvants have been widely employed to enhance immunity against specific antigens. An ideal adjuvant should be stable, biodegradable, and low cost, not induce system rejection and promote an immune response. Various adjuvant components have been investigated across diverse applications. Typically, adjuvants are employed to meet the following objectives: (1) to improve the effectiveness of immunization with vaccines for specific populations, such as newborns and the elderly; (2) enhance the immunogenicity of highly purified or recombinant antigens; (3) allow immunization with a smaller dose of the vaccine, reducing drug dosage. In the present review, we primarily focus on chemically synthesized compounds that can be used as built-in adjuvants. We elaborate the classification of these compounds based on the induced immune activation mechanism and summarize their application in various vaccine types.
Copyright © 2021. Published by Elsevier Masson SAS.

Entities:  

Keywords:  Built-in adjuvant; PRRs; STING; Synthetic vaccine; Vaccine; iNKT

Mesh:

Substances:

Year:  2021        PMID: 34688011     DOI: 10.1016/j.ejmech.2021.113917

Source DB:  PubMed          Journal:  Eur J Med Chem        ISSN: 0223-5234            Impact factor:   6.514


  3 in total

Review 1.  Crosstalk between ILC2s and Th2 CD4+ T Cells in Lung Disease.

Authors:  Lan-Lan Mi; Wei-Wei Guo
Journal:  J Immunol Res       Date:  2022-05-10       Impact factor: 4.493

Review 2.  Recent Advances in the Development of Toll-like Receptor Agonist-Based Vaccine Adjuvants for Infectious Diseases.

Authors:  Jing-Xing Yang; Jen-Chih Tseng; Guann-Yi Yu; Yunping Luo; Chi-Ying F Huang; Yi-Ren Hong; Tsung-Hsien Chuang
Journal:  Pharmaceutics       Date:  2022-02-16       Impact factor: 6.525

3.  Editorial: Understanding anti-trypanosomatid immune responses: The key to developing protective strategies against them.

Authors:  Cazorla S I; Alonso-Padilla Julio; W De Souza; Padilla A M
Journal:  Front Immunol       Date:  2022-09-21       Impact factor: 8.786

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.